Statins for people at low risk of cardiovascular disease

The Lancet

Volumn 380, Issue 9856, 2012, Pages 1817-

  Zomer, Ella ^a   Owen, Alice J ^a   Magliano, Dianna J ^a,b   Reid, Christopher M ^a  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; LETTER; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION;

EID: 84869410853     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62026-1     Document Type: Letter

References (3)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
2. Zomer E, Owen AJ, Magliano DJ, Liew D, Reid CM. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model. BMJ 2012; 344: e3657.
3. The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341-51.